TYRA News and Press, Tyra Biosciences Inc.

2024-05-10 08:17:18 ET More on Tyra Biosciences Seeking Alpha’s Quant Rating on Tyra Biosciences Historical earnings data for Tyra Biosciences Financial information for Tyra Biosciences Read the full article on Seeking Alpha For further details...

Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...

Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...

NEW YORK, NY / ACCESSWIRE / April 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information an...

2024-03-26 08:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-19 16:51:56 ET More on Tyra Biosciences Tyra Biosciences spikes on $200M private financing Seeking Alpha’s Quant Rating on Tyra Biosciences Historical earnings data for Tyra Biosciences Financial information for Tyra Biosciences Read ...

2024-03-19 16:50:59 ET More on Tyra Biosciences Tyra Biosciences spikes on $200M private financing Seeking Alpha’s Quant Rating on Tyra Biosciences Historical earnings data for Tyra Biosciences Financial information for Tyra Biosciences Read ...

Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights PR Newswire - Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Ini...

2024-03-16 06:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference PR Newswire CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-gener...